Abstract | BACKGROUND: METHODS: Twenty five patients with moderate to severe COPD, in stable phase of the disease, participated in this interventional, quasi-experimental study. All patients were received 40mg oral Zafirlukast per day for 2 weeks. Pulmonary function Test was performed both at the baseline and at the end of the study. Data were analyzed with paired t-test using SPSS v.16. RESULTS: The mean age of the patients was 67.29 (SD=5.56) years with the mean baseline for forced expiratory volume in first second (FEV1) equal to 41.79% (SD=14.96) of predicted value. After 2 weeks, the mean improvements in forced vital capacity (FVC), FEV1 and FEV1/FVC were 4.75% (SD=13.18), 3.71% (SD=9.19) and 9.33(SD=27.08), respectively. Zafirlukast produced a non-significant (p>0.05) bronchodilation, with maximum mean increase in FEV1 of 0.04 lit (3%) above baseline. CONCLUSION: Results showed that Zafirlukast has no considerable bronchodilatory effect in COPD. Present study consisted of a very short treatment period and it is possible that the extension of this period could possibly have more effects. Additional larger studies are needed to verify the impact of leukoterien receptor antagonists on improving the lung function in COPD patients.
|
Authors | Seyed Ali Javad Moosavi, Hanieh Raji, Baharak Tasorian, Elyas Mostafapour, Shahab Shahabi, Mohammad Purfakharan, Seyed-Mohammad Fereshtehnejad |
Journal | Medical journal of the Islamic Republic of Iran
(Med J Islam Repub Iran)
Vol. 27
Issue 2
Pg. 57-61
(May 2013)
ISSN: 1016-1430 [Print] Iran |
PMID | 23741166
(Publication Type: Journal Article)
|